



## PRESS RELEASE

18 October 2024 16:45:00 CEST

# Senzime announces that the first tranche of the directed share issue of MSEK 86 has been fully subscribed

Senzime AB (publ) ("Senzime" or the "Company") announced on 27 September 2024 the board of directors' resolution to carry out a directed share issue of up to 13,873,000 shares at the subscription price SEK 6.20 per share (the "Share Issue"). All newly issued shares in the first tranche of the Share Issue have been subscribed.

As previously communicated, the Share Issue will be carried out in two separate tranches. The first tranche ("**Tranche 1**") comprises 12,769,000 shares – which, with the subscription price mentioned above, correspond to approximately MSEK 79.2 – and is issued by the board of directors based on the authorization received at the annual general meeting on 16 May 2024. The persons entitled to subscribe for Tranche 1 were a limited number of investors who expressed a long-term commitment to the Company, including the new investor AB Strati and the existing shareholders Segulah Medical Acceleration, the Crafoord family, Fjärde AP-fonden, Carnegie Fonder, Swedbank Robur Fonder and Fredrik Rapp.

The second tranche ("**Tranche 2**") consists of a maximum of 1,104,000 shares – which, with the subscription price mentioned above, correspond to approximately MSEK 6.8 – and was resolved by the board of directors, subject to approval by an extraordinary general meeting of the Company. Notice of the extraordinary general meeting, scheduled for 23 October 2024, has been published in a separate press release. The persons entitled to subscribe for the shares in Tranche 2 are the board members Adam Dahlberg and Sorin J. Brull.

Tranche 1 is fully subscribed. Consequently, the total number of shares in the Company will increase by 12,769,000 from 119,705,523 to 132,474,523. The Company's share capital will increase by SEK 1,596,125 from SEK 14,963,190 to SEK 16,559,315. Tranche 1 thus results in a dilution of approximately 9.6 percent, based on the total number of shares in the Company after Tranche 1.

### Advisers

Zonda Partners has acted as financial advisor in connection with the Share Issue and Advokatfirman Lindahl has acted as legal advisor.

### For further information, please contact:

Philip Siberg, CEO of Senzime AB

Phone: +46 (0) 707 90 67 34, email: philip.siberg@senzime.com

Slavoljub Grujicic, CFO

Phone: +46 (0) 76 306 60 11, email: slavoljub.grujicic@senzime.com

*This press release is an English translation of the Swedish original. In the event of any discrepancies, the Swedish version shall prevail.*

## **About Sensime**

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. The company provides an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for accurate monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX: SNZZF). More information is available at [senzime.com](http://senzime.com).

### **For further information, please contact:**

---

Philip Siberg, CEO of Sensime AB

Phone: +46 (0) 707 90 67 34, e-mail: [philip.siberg@senzime.com](mailto:philip.siberg@senzime.com)

Slavoljub Grujicic, CFO

Phone: +46 (0) 76 306 60 11, e-mail: [slavoljub.grujicic@senzime.com](mailto:slavoljub.grujicic@senzime.com)

## **About Sensime**

---

Senzime, headquartered in Sweden, is a leading medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. The company provides an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for accurate monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX: SNZZF). More information is available at [senzime.com](http://senzime.com).

## **Attachments**

---

**Senzime announces that the first tranche of the directed share issue of MSEK 86 has been fully subscribed**